Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Incyte Corp INCY

Healthcare Biotechnology
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is... see more

Recent & Breaking News (NDAQ:INCY)

Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)

Business Wire January 9, 2017

Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease

Business Wire December 30, 2016

Research Reports Initiation on Biotech Stocks -- Incyte, Anavex Life Sciences, Portola Pharma, and Spectrum Pharma

PR Newswire December 29, 2016

Merus NV Executives Discuss Products And Plans Going Into 2017: 'We Have Milestones Coming Up'

Benzinga.com  December 23, 2016

Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher

Benzinga.com  December 21, 2016

Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations

Benzinga.com  December 21, 2016

Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

Business Wire December 21, 2016

CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

Canada NewsWire December 16, 2016

Incyte to Present at Upcoming Investor Conference

Business Wire December 13, 2016

Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)

Business Wire December 4, 2016

New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients

Canada NewsWire November 14, 2016

Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes

Canada NewsWire November 14, 2016

More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting

Business Wire November 3, 2016

New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo

PR Newswire November 2, 2016

Incyte to Present at Upcoming Investor Conference

Business Wire November 2, 2016

Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs

Business Wire November 1, 2016

Incyte to Report Third Quarter Financial Results

Business Wire October 14, 2016

The Street Is Seeing Higher Probability Of Success For Incyte's Melanoma Treatment

Benzinga.com  October 10, 2016

Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination with Keytruda® (pembrolizumab)

Business Wire October 7, 2016

Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)

Business Wire September 28, 2016